Eric Harstad is the Senior Director and Head of Nonclinical Safety Assessment at Theravance Biopharma US. He earned a BA in chemistry from Wartburg College in 1995 and a PhD in toxicology from the University of Kansas in 2001 studying Kupffer cell activation in cadmium-induced hepatotoxicity. As a postdoctoral fellow at the McArdle Laboratory for Cancer Research, he investigated novel biological functionality of the aryl hydrocarbon receptor in hepatovascular development. In 2005, Eric joined Bristol-Myers Squibb, focusing on transcriptional profiling in pilot toxicity studies and early drug development. From 2009 until 2016, he was a Senior Scientist and Toxicology Therapeutic Area Lead with the Genentech Safety Assessment group primarily supporting small and large molecule programs in Discovery and Early Development, with a focus on oncology, immunology and, infectious disease therapeutic areas. Eric has authored/co-authored 19 publications in the field of toxicology and was elected Vice President for NorCal SOT and Councilor for the Drug Discovery Toxicology Specialty Section. Eric has served as President of the NorCal SOT Regional Chapter, as a co-chair of the SOT Contemporary Concepts in Toxicology committee, and as a member of the American Board of Toxicology Standard of Knowledge and Question authoring committees. Since joining SOT in 1998, he has fostered development of new scientists in toxicology, including serving as an inaugural member of the SOT postdoctoral association, a judge for the 2011 and 2012 Drug Discovery Toxicology Specialty Section awards, the 2010 Intel Science Fair, and the 2017 Synopsys Science and Technology Championship, a continuing reviewer for ToxSci and TAAP, and an active member of the SOT mentor-mentee and Lunch with an Expert programs. Eric is also a Diplomate of the American Board of Toxicology.